Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial - Broome, C M; McDonald, V; Miyakawa, Y; ADVANCE Investigator Study Group (Lancet, 2023)
(10413):